Armand Girard Net Worth

The estimated Net Worth of Armand Girard is at least $7.22 millier dollars as of 11 November 2022. Mr. Girard owns over 6,500 units of GlycoMimetics Inc stock worth over $4,666 and over the last 5 years he sold GLYC stock worth over $2,550. In addition, he makes $0 as Senior Vice President et Chief Business Officer at GlycoMimetics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Girard GLYC stock SEC Form 4 insiders trading

Armand has made over 2 trades of the GlycoMimetics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 6,500 units of GLYC stock worth $6,825 on 11 November 2022.

The largest trade he's ever made was buying 6,500 units of GlycoMimetics Inc stock on 11 November 2022 worth over $6,825. On average, Armand trades about 1,768 units every 49 days since 2020. As of 11 November 2022 he still owns at least 29,161 units of GlycoMimetics Inc stock.

You can see the complete history of Mr. Girard stock trades at the bottom of the page.

Armand Girard biography

Armand Girard serves as Senior Vice President, Chief Business Officer of the Company. Mr. Girard has served as our Senior Vice President, Strategy and Corporate Development since January 2019 and previously as our Vice President, Corporate Development from April 2014 until January 2019. Prior to joining our company, Mr. Girard held the positions of Vice President for Technical Assessment and Senior Director for Business Development at Shire Pharmaceuticals, where he was responsible for numerous licensing transactions and acquisitions. He has more than 25 years of pharmaceutical/biotech experience, spanning a variety of product planning and new product development positions, with a number of companies, including Strakan Life Sciences, Pro-Virus, Inc. and Otsuka Pharmaceuticals. Mr. Girard holds an M.B.A. from St. Joseph’s University Haub School of Business and a B.A. from Lehigh University.

How old is Armand Girard?

Armand Girard is 51, he's been the Senior Vice President et Chief Business Officer of GlycoMimetics Inc since 2020. There are 11 older and 3 younger executives at GlycoMimetics Inc. The oldest executive at GlycoMimetics Inc is Dr. John L. Magnani, 68, who is the Sr. VP of Research & Chief Scientific Officer.

What's Armand Girard's mailing address?

Armand's mailing address filed with the SEC is C/O GLYCOMIMETICS, INC., 9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.

Insiders trading at GlycoMimetics Inc

Over the last 11 years, insiders at GlycoMimetics Inc have traded over $15,299,593 worth of GlycoMimetics Inc stock and bought 10,868,557 units worth $48,421,008 . The most active insiders traders include Scott D Sandell, Peter J Barris et M James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $38,210. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth $61,249.

What does GlycoMimetics Inc do?

at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.

Complete history of Mr. Girard stock trades at GlycoMimetics Inc

GlycoMimetics Inc executives and stock owners

GlycoMimetics Inc executives and other stock owners filed with the SEC include:

• Rachel King,
  President, Chief Executive Officer, Co-Founder, Director
• Brian Hahn,
  Chief Financial Officer
• Helen Thackray,
  Senior Vice President - Clinical Development, Chief Medical Officer
• John Magnani,
  Co-Founder, Senior Vice President, Chief Scientific Officer
• Rachel K. King,
  Pres, CEO & Director
• Brian M. Hahn,
  Sr. VP & CFO
• Timothy Pearson,
  Independent Chairman of the Board
• Daniel Junius,
  Independent Director
• Mark Goldberg,
  Independent Director
• Scott Jackson,
  Independent Director
• Patricia Andrews,
  Independent Director
• Scott Koenig,
  Independent Director
• Armand Girard,
  Senior Vice President, Chief Business Officer
• Bruce Johnson,
  Sr. VP & Chief Commercial Officer
• Armand Girard,
  Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel.
• Dr. John L. Magnani,
  Sr. VP of Research & Chief Scientific Officer
• Harout Semerjian,
  CEO, Pres & Director
• Dr. Eric J. Feldman M.D.,
  Sr. VP & Chief Medical Officer
• Christian Dinneen-Long,
  VP, Corp. Counsel & Corp. Sec.
• Henry Flanner,
  VP of Technical Operations
• Stephanie R. Irish,
  VP of Accounting
• Partners L P/Ilbiotechnolog...,
  
• Scott D Sandell,
  10% owner
• Franklin H Jr Top,
  Director
• Peter J Barris,
  10% owner
• Michael A Henos,
  Director
• M James Barrett,
  Director
• Enterprise Associates 10 L ...,
  
• John J. Baldwin,
  Director
• Chinmaya Rath,
  SVP and Chief Business Officer
• William M. Gust,
  Director
• Enterprise Associates 13 Lp...,
  
• Partners L P/Ilbiotechnolog...,
  
• Harout Semerjian,
  Chief Executive Officer
• Public Equities, L.P.Artal ...,
  
• Public Equities, L.P.Invus ...,
  
• Bruce S Johnson,
  SVP & Chief Commercial Officer
• Edwin Rock,
  Chief Medical Officer